News
July 5, 2023
A successful phase 1 study of an injectable lidocaine paste for spermatic cord block in men with chronic scrotal content pain
Patients with chronic scrotal content pain (CSCP) lack effective, noninvasive
treatment options. We aimed to determine the local and systemic safety, tolerability,
pharmacokinetics (PK), and efficacy of a long-lasting local anesthetic in patients with CSCP.
January 5, 2023
Sustained Therapeutics Advancing Clinical Trials for Novel Drug Delivery Platform
A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is evaluating a sustained release platform technology that could revolutionize how we treat pain and significantly improve the lives of individuals living with chronic pain.
March 30, 2023
Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform
A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population. Sustained Therapeutics’ first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.
